非戈替尼治疗溃疡性结肠炎的综合安全性分析:SELECTION与SELECTIONLTE研究结果
本文报告SELECTION(2b/3期)及其长期扩展研究SELECTIONLTE的综合安全性数据,纳入1348例中重度活动性溃疡性结肠炎成人患者,累计暴露3326.2患者年。非戈替尼200mg与100mg总体耐受良好,未发现非预期安全性信号,严重感染、血栓栓塞事件和主要不良心血管事件的发生率在各治疗组均持续较低。
要点
- 非戈替尼200mg和100mg在中重度活动性溃疡性结肠炎患者中耐受良好,未发现非预期安全性信号。
- 严重感染、血栓栓塞事件和主要不良心血管事件的暴露调整发生率在各治疗组均持续较低。
- 带状疱疹的暴露调整发生率在非戈替尼200mg组数值上高于安慰剂组。
核心结论
- 非戈替尼200mg和100mg在中重度活动性溃疡性结肠炎患者中耐受良好,无论既往生物制剂暴露史或年龄如何,均未发现非预期安全性信号。
研究设计与样本
- 整合2b/3期SELECTION研究(NCT02914522)及其正在进行的长期扩展研究SELECTIONLTE(NCT02914535)的安全性数据。
- 分析对象为接受非戈替尼200mg、非戈替尼100mg或安慰剂每日一次治疗的中重度活动性溃疡性结肠炎成人患者,涵盖11周诱导研究、47周维持研究(如适用)及SELECTIONLTE(如适用)。
- 本次期中分析纳入1348例患者,累计暴露3326.2患者年。
- 报告治疗中出现的不良事件的每100删失患者年暴露调整发生率及其95%置信区间。
- 部分不良事件数据按年龄和既往生物制剂暴露状态进行亚组呈现。
主要发现
- 严重感染、血栓栓塞事件和主要不良心血管事件的暴露调整发生率在各治疗组均持续较低。
- 发生主要不良心血管事件的大多数患者具有心血管危险因素。
- 带状疱疹的暴露调整发生率在非戈替尼200mg组数值上高于安慰剂组。
- 感染发生率在生物制剂经治患者中数值上高于生物制剂初治患者。
- 65岁及以上患者中某些不良事件的发生率较高,符合预期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). AIM: To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long-term extension study SELECTIONLTE (NCT02914535). METHODS: Safety outcomes were analysed in adults with moderately to severely active UC who received FIL200, filgotinib 100 mg (FIL100) or placebo once daily throughout the 11-week SELECTION induction study, the 47-week SELECTION maintenance study (if applicable) and SELECTIONLTE (if applicable). Exposure-adjusted incidence rates (EAIRs) per 100 censored patient-years of exposure with 95% confidence intervals were reported for treatment-emergent adverse events (AEs). Certain AE data were presented in subgroups, including age and prior biologic exposure status. RESULTS: This interim analysis included 1348 patients representing 3326.2 patient-years of exposure. Baseline characteristics of patients entering SELECTION were similar across treatment groups. EAIRs for serious infection, thromboembolic events and major adverse cardiovascular events (MACE) were consistently low across treatment groups. Most patients with MACE had cardiovascular risk factors. The EAIR for herpes zoster was numerically higher for FIL200 than for placebo. Infection incidences were numerically higher in biologic-experienced than biologic-naive patients. Higher incidences of certain AEs in patients 65 years of age or older were as expected. Four deaths occurred, including three cardiovascular deaths, none of which was considered related to filgotinib. CONCLUSION: FIL200 and FIL100 were well tolerated with no unexpected safety signals in patients with moderately to severely active UC, regardless of previous biologic exposure or age. GOV IDENTIFIERS (NCT NUMBERS): NCT02914522, NCT02914535.
引用
- Schreiber S, Rogler G, Watanabe M, et al. Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE. Aliment Pharmacol Ther. 2023. PMID: 37718932. doi:10.1111/apt.17674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。